FDA
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals names Dr. Jeymi Tambiah as chief medical officer
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
-
-
-
-
-
-
-
Eupraxia reports positive results from highest dose in EoE trial
-
-
-
-
-
-
-
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals (EPRX) Strengthens Senior Management Team
-
322,093 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

